Q2 2025 Management View Co-CEO Justin B. Klee highlighted "meaningful progress across our clinical programs" in the first half of 2025, emphasizing Avexitide as the lead asset, which is an ...

Day One Biopharmaceuticals poised for growth with OJEMDA success and FIREFLY-2 catalysts. See here to know why we are bullish ...

As Ethereum eyes the $5,000 mark amid renewed bullish momentum across the crypto market, investors are turning their ...

Free-to-play time-traveling strategic RPG Reverse: 1999 just launched its biggest collaboration yet, its first to ever launch ...

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...

Despite progress on several clinical programs and tighter cost controls, there was a major decline in cash reserves, with cash and cash equivalents (GAAP) decreasing from $49.0 million as of December ...

Tampa City Council approved a resolution a $1.83 million contract to begin repairs at Sulphur Springs Pool. FOX 13's Kylie ...

Eli Lilly stock beats Q2 estimates with strong sales but faces competitive risks and high valuation. Here's why investors may ...

Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill ...

The summer heat may be the focus for many in Holland this August, but anticipation is growing for the more than $11 million ...

Now, new clinical trial results suggest that an oral form of this medication may be coming soon—and the results so far are ...

Norris must not only sustain his form but also navigate the increasingly tense dynamics within the McLaren garage.